1. Adams GE, Ahmed I, Sheldon PW, Stratford IJ (1984) Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 49: 571–577
2. Boyd MR, Stiko AW, Sasame HA (1979) Metabolic activation of nitrofurantoin—possible implications for carcinogenesis. Biochem Pharmacol 28: 601–606
3. Butchart GAM, Stevens MFG, Gunn BC (1978) Medicinal nitrocompounds: II. Search for ortho-interactions in tumour-inhibitory 2,4-dinitrophenylaziridines. J Chem Soc Perkin Trans 1: 956–963
4. Chapman JD, Raleigh JA, Pedersen JE, Ngan J, Shum FY, Meeker BE, Urtasun RC (1979) Potentially three distinct roles for hypoxic cell sensitizers in the clinic. In: Okada S, Imamura M, Terashima T, Yamaguchi H (eds) Radiation research: Proceedings of the 6th International Congress of Radiation Research, Tokyo. Japanese Association for Radiation Research, Tokyo, pp 885–892
5. Cobb LM, Connors TA, Elson LA, Khan AH, Mitchley BCV, Ross WCJ, Whisson ME (1969) 2,4-Dinitro-5-ethylene iminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the walker carcinoma 256. Biochem Pharmacol 18: 1519–1527